Document Detail


Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
MedLine Citation:
PMID:  3315606     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The safety and tolerance data of the preliminary results of a randomised, parallel group, multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in patients with myocardial infarction are presented. The frequency of side effects was similar in the 2 groups. The most frequently encountered side effect was bleeding, overwhelmingly from the groin puncture site from angiography. There was no significant difference between amount or incidence of bleeding complications between the two groups, as measured by number of bleeding episodes, transfusion requirements, or mean drop in haematocrit or haemoglobin.
Authors:
R L Rothbard
Related Documents :
21309746 - C-terminal provasopressin (copeptin) as a prognostic marker after acute non-st elevatio...
8237806 - Effects of long-term oral magnesium chloride replacement in congestive heart failure se...
14739626 - Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial ...
10079776 - Potential cost effectiveness of tissue plasminogen activator among patients previously ...
11950436 - Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofo...
15733666 - Normal patterning of the coronary capillary plexus is dependent on the correct transmur...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  276-8     Citation Subset:  IM    
Affiliation:
University of Rochester, School of Medicine and Dentistry.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Clinical Trials as Topic
Fibrinolytic Agents / adverse effects*,  therapeutic use
Hematocrit
Hemoglobins / drug effects
Hemorrhage / chemically induced
Humans
Myocardial Infarction / drug therapy*
Plasminogen / adverse effects*,  therapeutic use
Random Allocation
Streptokinase / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Hemoglobins; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myo...
Next Document:  Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase...